Navigation Links
Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders
Date:3/31/2011

ni Bio's lead development programs is evaluating an FDA-approved, off-patent drug, AAT, for the treatment of Type 1 diabetes.  Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of bacterial and viral disorders, biohazards, diabetes and transplant rejection.  For additional information, please visit www.omnibiopharma.com.

Forward-Looking StatementsSome of the statements made in this press release are forward-looking statements that reflect management's current views and expectations with respect to future events, including the expansion and commencement of clinical trials and the outcome and expenses of such trials. These forward-looking statements are not a guarantee of future events and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual events to differ materially from those expressed or implied by the statements.  These risks and uncertainties are based on a number of factors, including but not limited to receipt of adequate funding to expand and commence clinical trials; receipt of applicable regulatory approvals for clinical trials, the risks related to the ownership and enforceability of our licensed intellectual property necessary to conduct the clinical trials and the business risks disclosed in our SEC filings, especially the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2010.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Omni Bio Pharmaceutical, Inc.

Hayden IR  Edward C. Larkin, Chief Operating Officer

Brett Maas, Managing Partner(720) 488-4708

(646) 536-7331 Email: brett@haydenir.com'/>"/>

SOURCE Omni Bio Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
2. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
3. National Pharmaceutical Council Welcomes New Member, Otsuka America Pharmaceutical, Inc.
4. Shengtai Pharmaceutical, Inc Announces Appointment of New Chief Financial Officer
5. Shengtai Pharmaceutical, Inc. Reports Financial Results for the Third Quarter and the First Nine Months of Fiscal Year 2010
6. Ortho-McNeil Pharmaceutical, LLC Pleads Guilty to Illegal Promotion of Topamax and is Sentenced to Criminal Fine of $6.14 Million
7. WellSpring Pharmaceutical, American Gastroenterological Association, and Steven Bramson of Humanscale Partner With MediaPlanet to Publish One of the Largest Digestive Wellness Campaigns in U.S. History to Overcome Upset Stomach, Nausea, IBS, and Deb
8. Masters Pharmaceutical, Inc. Appoints Wayne A. Corona to President and Chief Operating Officer
9. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Hologic, Inc. (NASDAQ: HOLX ), today ... Chief Executive Officer, will preside over the NASDAQ Stock ... day of Breast Cancer Awareness Month. In his remarks, ... the important benefits of Hologic,s 3D Mammography technology, the ... superior to traditional mammography. This is the ...
(Date:9/30/2014)... , Sept. 30, 2014 This ... for molecular imaging informatics solutions including nuclear imaging ... and comparison. The study assesses the size of ... 2010 and 2013, and projects future growth based ... as the dynamics taking place in the broader ...
(Date:9/30/2014)... 30, 2014 Aileron Therapeutics, Inc. - ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - Product ... the Aileron Therapeutics, Inc.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Aileron Therapeutics, ... therapeutics assessment by drug target, mechanism of action ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
... , STAMFORD, Conn., Nov. 13 ... will be releasing a free trial version of its Zargis ... conference, taking place this November 15-17 in Orlando. Zargis is ... the companion hardware -- the 3M Littmann Electronic Stethoscope Model ...
... BERWYN, Pa., Nov. 13 /PRNewswire-FirstCall/ -- Encorium Group, ... multinational clinical research organization (CRO) conducting studies in over ... and biotechnology companies, today announced that it has appointed ... 7, 2009. Ms. Laitinen, age 43, will replace ...
Cached Medicine Technology:Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 2Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 3Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors 2Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors 3
(Date:10/1/2014)... has shown that more than 80 per cent of ... The study found that medicines called ,JAK inhibitors, halted ... that is present in more than 80 per cent ... or are in clinical trials, for diseases including rheumatoid ... cancer is the second-most common cancer in Australia with ...
(Date:10/1/2014)... Despite a policy focus on expanding access to ... population continues to have significant dental disease. In ... the American Dental Association , researchers from Tufts ... of Dental Medicine report on the first large-scale ... provided by caregivers to adults with developmental disabilities. ...
(Date:10/1/2014)... October 01, 2014 Bedros Keuilian is ... Boot Camp fitness boot camps, he’s also considered the ... , with sold out business summits, a line of ... consultant to a recent Spike TV reality show to ... now is the time for personal trainers and fitness ...
(Date:10/1/2014)... Farmington Company today announced it has ... visual identity helping brokers, consultants and companies to ... create greater benefit communication synergies. They unveiled a ... customers to better leverage Farmington Company’s industry-tested experience ... the rebrand is the refreshed tagline: For the ...
(Date:10/1/2014)... Jupiter, FL (PRWEB) October 01, 2014 ... Begley, Jr., scheduled to broadcast on Monday, October 20, ... In this episode, Innovations will go behind the scenes ... prevention programs. This segment will explore the practical help ... young adults, which teaches the warning signs of abuse, ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... plc (NYSE/LSE: CCL; NYSE CUK) today announced a financial ... of which will be incurred in the second fiscal ... cruise itineraries for the six-week period ended June 15, ... (CDC) recommendation against non-essential travel to Mexico. The CDC ...
... recently updated the NCCN Guidelines for Central Nervous ... recommendation to use bevacizumab as a single agent ... integration of a patient,s Karnofsky Performance Status (KPS) ... range for adjuvant therapy options in patients with ...
... disease is no more dangerous than regular flu , , MONDAY, ... New York City public school died Sunday night of complications ... the United States to die from the disease that was ... that the death was not surprising, because even a normal ...
... Model Lowers Claims Costs by Reducing UtilizationCOLUMBUS, Ohio, May ... solutions to runaway healthcare costs, Quantum Health, Inc. announced ... of $1,092 per employee, or 14%, in 2008. Over ... healthcare cost trend to 4%-5% with no reduction in ...
... Hispanics agree that the health of the entire family ... ownRIDGEFIELD, Conn., May 18 The economic downturn is ... the Hispanic community, with parents prioritizing their children,s health ... consider it equally important for parents to take care ...
... and Only Long-Acting Antipsychotic Therapy Available for Bipolar ... of Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced the U.S. ... Supplemental New Drug Applications (sNDAs) for the use ... both monotherapy and adjunctive therapy to lithium or ...
Cached Medicine News:Health News:Carnival Corporation & plc Reports Financial Impact of Itinerary Changes Responding to H1N1 Influenza Mexico Travel Advisory; Plans Rapid Return to Popular Mexican Ports 2Health News:NCCN Updates Guidelines for Central Nervous System (CNS) Cancers 2Health News:NCCN Updates Guidelines for Central Nervous System (CNS) Cancers 3Health News:NYC School Assistant Principal Is Latest Swine Flu Fatality 2Health News:NYC School Assistant Principal Is Latest Swine Flu Fatality 3Health News:NYC School Assistant Principal Is Latest Swine Flu Fatality 4Health News:NYC School Assistant Principal Is Latest Swine Flu Fatality 5Health News:NYC School Assistant Principal Is Latest Swine Flu Fatality 6Health News:NYC School Assistant Principal Is Latest Swine Flu Fatality 7Health News:NYC School Assistant Principal Is Latest Swine Flu Fatality 8Health News:NYC School Assistant Principal Is Latest Swine Flu Fatality 9Health News:NYC School Assistant Principal Is Latest Swine Flu Fatality 10Health News:NYC School Assistant Principal Is Latest Swine Flu Fatality 11Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 2Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 3Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 4Health News:New Research Finds Recession Has Greater Impact on Health of Parents than Children with Specific Findings on Hispanics 2Health News:New Research Finds Recession Has Greater Impact on Health of Parents than Children with Specific Findings on Hispanics 3Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 2Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 3Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 4Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 5Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 6Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 7Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 8Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 9Health News:FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 10
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: